SciClone Pharmaceuticals, Inc. (SCLN) said that it now expects fiscal 2009 revenues of about $72.4 million, compared to prior range of $70 million - $72 million. Analysts polled by Thomson Reuters expect the company to report revenues of $72.30 million for fiscal 2009.
Cash, cash equivalents, short and long-term investments are anticipated to be approximately $31.8 million at December 31, 2009, compared with $29.7 million at December 31, 2008.
The company expects 2010 sales revenue of $82 million to $85 million, a 15% increase over 2009. Analysts polled by Thomson Reuters expect the company to report revenues of $73.57 million for fiscal 2010.
"During 2009, we executed on our corporate strategy of managing the company as a profit-driven specialty pharmaceutical business with a strong pipeline to fuel future growth. We expect to achieve significant full year operating profitability during 2009 and are very pleased with both our commercial sales growth and cash position. Given the strong performance of our international commercial operations and careful expense management, we expect profits to continue to grow in 2010." said, Friedhelm Blobel, SciClone's President and Chief Executive Officer.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.